A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
不适用
提前终止
NCT05966740
| 适应症 | Venous Thromboembolism |
|---|
| 分期 | 不适用 |
|---|
| 申办方 | Boehringer Ingelheim |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 5 人 |
|---|
| 开始日期 | 2024年4月19日 |
|---|
| 完成日期 | 2025年4月28日 |
|---|
| 结果公布日 | 2026年6月2日 |
|---|
摘要
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
Cumulative Incidence of Clinically Relevant Bleeding Events
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days. · Participants
| Pradaxa-treated Patients | 1 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。